Webinar replay

Partner of Choice. By Choice. How AbbVie Topped the Partnering 2030 Survey

In 2022 Inova surveyed more than 100 biotechs worldwide for its Partnering 2030 report​ to determine which pharma company offered the very best partnering experience. The clear winner: AbbVie. Praised by biotechs for its good working relationships and commitment to achieving business and scientific objectives, AbbVie has established itself as a partner of choice – and it’s not by accident. ​

In this exclusive webinar, Niels Emmerich, Vice President and Global Head of Search & Evaluation, explains how AbbVie chose to position itself as a partner of choice for biotechs, the best practices it implemented to achieve this position, and what the company is seeking in partners in 2023 and beyond.​ ​

Watch the replay to learn:​

  • How important the 'first touch' is in biopharma partnering​
  • Effective strategies for getting your foot in the door at a top pharma company
  • What partnering opportunities AbbVie is seeking in 2023​
Watch this replay to get expert insights from our panelists:
Niels Emmerich
Niels Emmerich
Vice President, Global Head S&E
Caroline Edlund Toulemonde
Caroline Toulemonde
Chief Strategy Officer

Please complete the form below

All fields marked with a * are required.

By submitting this form, you agree to the storing and processing of your
personal data by Inova as detailed in the Privacy Statement.

About Inova

Inova accelerates partnering for the future of medicine. Our cloud-based solutions help life science companies manage their biopharma opportunities more efficiently. They find all their partnering information in one place, track their deals and alliances easily and report on their pipeline and activities in seconds.
We have also developed strategic partnerships that make data from the 20 biggest biopharma events automatically available in Inova, providing our users with always up-to-date company and contact information. Over 150 life science companies, including 50% of the top 50 pharmaceutical companies and many midsize pharma and innovative biotechs already use Inova.